Travere Therapeutics (TVTX) drew investor attention on 4 August 2026 after reporting second quarter results that combined ...

Earlier this week, Travere Therapeutics reported Q2 2026 results showing revenue rising to US$169.58 million from US$114.45 ...

Travere Therapeutics stock has delivered a very strong 341.0% return over the past five years, and the current valuation ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Tuesday reported a loss of $34.8 million in its second quarter. The San Diego-based company said it had a loss of 37 cents per ...

(Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conf ...

Q2 reframed FILSPARI as a two-indication commercial story, with management emphasizing it was "the first quarter with FILSPARI commercially available across both IgA nephropathy and FSGS" (President, ...

Travere Therapeutics, Inc. ( TVTX) Q2 2026 Earnings Call August 4, 2026 4:30 PM EDT Good morning, and welcome to Travere Therapeutics Second Quarter 2026 Financial Results Conference Call. Today's ...

3 Under-the-Radar Healthcare Companies Travere Therapeutics (NASDAQ:TVTX) reported second-quarter results marked by record ...

Travere Therapeutics Inc. TVTX shares surged 13.44% to $63.55 in after-hours trading on Tuesday after the biopharmaceutical ...

Mirum Pharmaceuticals MIRM reported a loss of 80 cents per share (excluding certain one-time expenses) for the second quarter ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand ...

Trent Harrison, the founder of Ransomed Bodies Training, is proud to announce the official release of his highly anticipated ...